Eating disorders and GLP-1 RA medications: Shared position statement
A new position statement from the eating disorder and weight-related care sectors calls for greater understanding and consideration of eating disorders when GLP-1 medications are prescribed.
GLP-1 medications are being prescribed more widely, and for many people with health conditions such as type 2 diabetes, the benefits are significant. However, GLP-1 medications can pose a serious risk to people who have a history of, or are currently experiencing, an eating disorder. This includes exacerbation of weight loss, fear of weight gain, overevaluation of shape and weight, and interference with eating disorder treatment (e.g. regular eating).
Today, the National Eating Disorders Collaboration (NEDC) joins 19 organisations in releasing a position statement on GLP-1 receptor agonists and eating disorders. It reflects a shared view that all people deserve safe, evidence-based care that looks after both physical and psychological health.
What the position statement calls for
-
Recognise that eating disorders occur across all body sizes and may be present in people seeking obesity* management, including GLP-1 based therapies. A personal history of an eating disorder is a recognised risk factor for recurrence.
-
Be aware that people with an eating disorder, including anorexia nervosa, may actively seek access to medication. This risk may be heightened in online service models, where prescribers are unable to perform a physical examination and where weight or BMI may be misreported.
-
Discuss disordered eating during obesity* management consultations, with referral for assessment and evidence-based treatment where an eating disorder is suspected or identified.
-
Arrange additional support for people where needed including nutritional and physical activity guidance and psychological care. (GLP-1 based therapies have clear therapeutic indications which guide prescribing).
-
Work to reduce weight stigma and eating disorder stigma in clinical practice and patient communication.
-
Consider language that is used to discuss weight.
The statement also raises concern about GLP-1 products from unregulated and illicit sources and calls for coordinated action to reduce harm while ensuring that people with a clinical need can access evidence-based care without unnecessary barriers. It also acknowledges that the evidence is still developing, calling for investment in research that includes people experiencing or at risk of eating disorders.
Why this matters to NEDC
People with higher weight are too often under recognised and undertreated for eating disorders, of which weight stigma and eating disorder stigma play a role. This position statement sits within a larger body of work that followed the development of the Management of Eating Disorders in People with Higher Weight: Clinical Practice Guideline, with the aim of improving the prevention, identification, response and treatment of eating disorders in people with higher weight.
It also reflects what we have heard from people with lived experience, clinicians, and service leaders through many conversations. The statement is aligned with the recent Delphi study on eating disorders and GLP-1 medications: proactive screening before and during treatment, and collaborative, whole-person care.
A note on language
*NEDC uses “higher weight” rather than “obesity”, a term many people find stigmatising and harmful. Our language factsheet explains why and offers alternatives. The term “obesity” is used in the position statement as the statement was developed by organisations across the weight-related care and eating disorder sectors and is used in medical practice and research. When directly referencing content from the statement, NEDC uses the word obesity with an accompanying language note.
Resources
Our website provides information and resources to support the implementation of the Position Statement’s recommendations including guidance on screening, referral pathways, and how to identify and reduce weight stigma in practice. Find more information here. You can also read the full position statement here.
For support with eating disorders or body image concerns, contact the Butterfly National Helpline on 1800 33 4673 or visit www.butterfly.org.au